ObsEva SA
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.08
- Today's High:
- $0.098
- Open Price:
- $0.08
- 52W Low:
- $0.065
- 52W High:
- $0.287
- Prev. Close:
- $0.083
- Volume:
- 128096
Company Statistics
- Market Cap.:
- $11.00 million
- Book Value:
- -0.03
- Revenue TTM:
- $3.71 million
- Operating Margin TTM:
- -1240.74%
- Gross Profit TTM:
- $17000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -50.26%
- Return on Equity TTM:
- -373.98%
Company Profile
ObsEva SA had its IPO on 2017-01-26 under the ticker symbol OBSV.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. ObsEva SA has a staff strength of 48 employees.
Stock update
Shares of ObsEva SA opened at $0.08 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.08 - $0.1, and closed at $0.08.
This is a +1.2% increase from the previous day's closing price.
A total volume of 128,096 shares were traded at the close of the day’s session.
In the last one week, shares of ObsEva SA have slipped by -8.79%.
ObsEva SA's Key Ratios
ObsEva SA has a market cap of $11.00 million, indicating a price to book ratio of 0.7249 and a price to sales ratio of 4.0246.
In the last 12-months ObsEva SA’s revenue was $3.71 million with a gross profit of $17000 and an EBITDA of $-46063000. The EBITDA ratio measures ObsEva SA's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ObsEva SA’s operating margin was -1240.74% while its return on assets stood at -50.26% with a return of equity of -373.98%.
In Q4, ObsEva SA’s quarterly earnings growth was a positive 0% while revenue growth was a negative 85.2%.
ObsEva SA’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.74 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ObsEva SA’s profitability.
ObsEva SA stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2196. Its price to sales ratio in the trailing 12-months stood at 4.0246.
ObsEva SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $16.54 million
- Total Liabilities
- $7.19 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $15000
- Dividend Payout Ratio
- 0%
ObsEva SA ended 2024 with $16.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $16.54 million while shareholder equity stood at $8.48 million.
ObsEva SA ended 2024 with $0 in deferred long-term liabilities, $7.19 million in other current liabilities, 8755000.00 in common stock, $-472819000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.42 million and cash and short-term investments were $8.42 million. The company’s total short-term debt was $3,027,000 while long-term debt stood at $0.
ObsEva SA’s total current assets stands at $15.99 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $252000.00 compared to accounts payable of $0 and inventory worth $0.
In 2024, ObsEva SA's operating cash flow was $0 while its capital expenditure stood at $15000.
Comparatively, ObsEva SA paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.08
- 52-Week High
- $0.287
- 52-Week Low
- $0.065
- Analyst Target Price
- $6.5
ObsEva SA stock is currently trading at $0.08 per share. It touched a 52-week high of $0.287 and a 52-week low of $0.287. Analysts tracking the stock have a 12-month average target price of $6.5.
Its 50-day moving average was $0.12 and 200-day moving average was $0.27 The short ratio stood at 0.15 indicating a short percent outstanding of 0%.
Around 201.6% of the company’s stock are held by insiders while 1342.3% are held by institutions.
Frequently Asked Questions About ObsEva SA
Similar Industry Stocks (Biotechnology & Medical Research)
Most Active
Top Gainers
Top Losers
About
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.